hcc1937 crl 2336 human breast cancer cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC hcc1937 crl 2336 human breast cancer cells
    SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and <t>HCC1937</t> breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.
    Hcc1937 Crl 2336 Human Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1937 crl 2336 human breast cancer cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1937 crl 2336 human breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Impact of in vitro SARS-CoV-2 infection on breast cancer cells"

    Article Title: Impact of in vitro SARS-CoV-2 infection on breast cancer cells

    Journal: Scientific Reports

    doi: 10.1038/s41598-024-63804-3

    SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.
    Figure Legend Snippet: SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.

    Techniques Used: Western Blot, Expressing, Infection, Real-time Polymerase Chain Reaction, Comparison

    Effect of SARS-CoV-2 infection on breast cancer cell proliferation and motility. ( a ) MTT proliferation assay of MCF7, MDA-MB-231 and HCC1937 breast cancer cells after 72 h or 7 days of SARS-CoV-2 infection. Uninfected cells served as controls. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 by unpaired two-tailed t test. ( b ) Confluent monolayers of MCF7, MDA-MB-231 and HCC1937 cells were infected with SARS-CoV-2. After 2 h of infection, the viral inoculum was removed, and gap wounds were generated by mechanical scratching. Cell migration into the wounded area was observed at 0, 4 and 24 h p.i. Histograms showing the extent of wound closure at the indicated time points are presented, with data shown as the percentages of wound closure at a specific time point compared to 0 h. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance.
    Figure Legend Snippet: Effect of SARS-CoV-2 infection on breast cancer cell proliferation and motility. ( a ) MTT proliferation assay of MCF7, MDA-MB-231 and HCC1937 breast cancer cells after 72 h or 7 days of SARS-CoV-2 infection. Uninfected cells served as controls. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 by unpaired two-tailed t test. ( b ) Confluent monolayers of MCF7, MDA-MB-231 and HCC1937 cells were infected with SARS-CoV-2. After 2 h of infection, the viral inoculum was removed, and gap wounds were generated by mechanical scratching. Cell migration into the wounded area was observed at 0, 4 and 24 h p.i. Histograms showing the extent of wound closure at the indicated time points are presented, with data shown as the percentages of wound closure at a specific time point compared to 0 h. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance.

    Techniques Used: Infection, Proliferation Assay, Two Tailed Test, Generated, Migration, Comparison

    Effect of SARS-CoV-2 infection on breast cancer cell gene expression profiles. MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2 lineage B1, and gene expression profile analysis was performed at 24 h and 7 days p.i. ( a ) Number of DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cell line 24 h p.i. ( b ) Overlapping upregulated DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cellular model 24 h p.i. ( c-e ) Bubble plots of the top 10 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected cells as determined by preranked GSEA. ( f ) Bubble plot of the only 4 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected HCC1937 cells at 7 days p.i., as determined by preranked GSEA. The X-axis shows the normalized enrichment score (NES). The bubble area is proportional to the size of the gene set, and the bubble color represents the FDR q value.
    Figure Legend Snippet: Effect of SARS-CoV-2 infection on breast cancer cell gene expression profiles. MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2 lineage B1, and gene expression profile analysis was performed at 24 h and 7 days p.i. ( a ) Number of DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cell line 24 h p.i. ( b ) Overlapping upregulated DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cellular model 24 h p.i. ( c-e ) Bubble plots of the top 10 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected cells as determined by preranked GSEA. ( f ) Bubble plot of the only 4 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected HCC1937 cells at 7 days p.i., as determined by preranked GSEA. The X-axis shows the normalized enrichment score (NES). The bubble area is proportional to the size of the gene set, and the bubble color represents the FDR q value.

    Techniques Used: Infection, Expressing, Comparison

    breast cancer cell line hcc1937  (Thermo Fisher)


    Bioz Verified Symbol Thermo Fisher is a verified supplier
    Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Thermo Fisher breast cancer cell line hcc1937
    Breast Cancer Cell Line Hcc1937, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer cell line hcc1937/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast cancer cell line hcc1937 - by Bioz Stars, 2024-07
    86/100 stars

    Images


    Structured Review

    Korean Cell Line Bank hcc1937 human breast cancer cells
    Hcc1937 Human Breast Cancer Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1937 human breast cancer cells/product/Korean Cell Line Bank
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1937 human breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars

    Images

    hcc1937 breast cancer cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC hcc1937 breast cancer cells
    CAFs conferred more potential to breast cancer cells in growth and chemoresistance than NFs. (a) Impact of coculture with NFs or CAFs on the growth of <t>HCC1937</t> breast cancer cells. (b) Influence of coculture with NFs or CAFs on the sensitivity of HCC1937 breast cancer cells to doxorubicin. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Hcc1937 Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1937 breast cancer cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1937 breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Biological differences between normal and cancer-associated fibroblasts in breast cancer"

    Article Title: Biological differences between normal and cancer-associated fibroblasts in breast cancer

    Journal: Heliyon

    doi: 10.1016/j.heliyon.2023.e19803

    CAFs conferred more potential to breast cancer cells in growth and chemoresistance than NFs. (a) Impact of coculture with NFs or CAFs on the growth of HCC1937 breast cancer cells. (b) Influence of coculture with NFs or CAFs on the sensitivity of HCC1937 breast cancer cells to doxorubicin. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: CAFs conferred more potential to breast cancer cells in growth and chemoresistance than NFs. (a) Impact of coculture with NFs or CAFs on the growth of HCC1937 breast cancer cells. (b) Influence of coculture with NFs or CAFs on the sensitivity of HCC1937 breast cancer cells to doxorubicin. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used:

    CAFs conferred more potential to breast cancer cells in migration and invasion than NFs. Representative photomicrographs (a, b) and quantification (c–e) depicting the migration (a) and invasion (b) under distinct coculture conditions for HCC1937 cells as assessed through transwell assay. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: CAFs conferred more potential to breast cancer cells in migration and invasion than NFs. Representative photomicrographs (a, b) and quantification (c–e) depicting the migration (a) and invasion (b) under distinct coculture conditions for HCC1937 cells as assessed through transwell assay. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used: Migration, Transwell Assay

    hcc1937 breast cancer cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC hcc1937 breast cancer cells
    Hcc1937 Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1937 breast cancer cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1937 breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars

    Images


    Structured Review

    Korean Cell Line Bank brca1 deficient hcc1937 human breast cancer cells
    Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of <t>BRCA1‐mutant</t> <t>HCC1937</t> breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.
    Brca1 Deficient Hcc1937 Human Breast Cancer Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/brca1 deficient hcc1937 human breast cancer cells/product/Korean Cell Line Bank
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    brca1 deficient hcc1937 human breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform"

    Article Title: Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform

    Journal: Advanced Science

    doi: 10.1002/advs.202302253

    Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of BRCA1‐mutant HCC1937 breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.
    Figure Legend Snippet: Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of BRCA1‐mutant HCC1937 breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.

    Techniques Used: In Vitro, Variant Assay, Confocal Microscopy, Mutagenesis, Labeling, Sequencing, Formulation

    Functional validation of CRISPR/Cas9‐drug conjugates for combination treatment in cancer cells in vitro. a) Schematic showing the principle of synthetic lethality induced by Cas9‐Olap conjugate RNPs, based on the function of olaparib and RAD52 gene editing in BRCA‐mutant cancer. b) Characterization of Cas9‐Olap conjugates prepared with the various Cas9‐AzF variants: olaparib conjugation efficiencies, cleavage activities, and indel frequencies. c) Representative sequence data by targeting deep sequencing of HCC1937 cells treated with Cas9‐Olap RNPs complexed with CMAX for 48 h at 500 nM Cas9. d–f) Combinatorial effect of treating Cas9‐Olap RNPs prepared with the Y373 variant, on anti‐proliferation of cells using conventional carriers for 72 h (500 nM Cas9; n = 3, One‐way ANOVA, ** p < 0.01, *** p < 0.001, **** p < 0.0001). d) Effect of Cas9‐Olap RNPs prepared by conjugation of olaparib via azido (Cas9‐Olap1), sulfhydryl (Cas9‐Olap2), and both azido and sulfhydryl (Cas9‐Olap3) groups, complexed with CMAX and treated to HCC1937 cells. e,f) Comparison of the anti‐proliferation effect in HCC1937 and MDA‐MB‐231 cells using e) CMAX, and f) TAT peptide (molar ratio of Cas9:TAT = 1:10) as the carrier. Concentration of free olaparib was adjusted to the conjugated olaparib concentration for the corresponding Cas9‐Olap conjugate in each group. Cas9‐Olap conjugates were complexed with RAD52 sgRNA at a molar ratio of 1:1.
    Figure Legend Snippet: Functional validation of CRISPR/Cas9‐drug conjugates for combination treatment in cancer cells in vitro. a) Schematic showing the principle of synthetic lethality induced by Cas9‐Olap conjugate RNPs, based on the function of olaparib and RAD52 gene editing in BRCA‐mutant cancer. b) Characterization of Cas9‐Olap conjugates prepared with the various Cas9‐AzF variants: olaparib conjugation efficiencies, cleavage activities, and indel frequencies. c) Representative sequence data by targeting deep sequencing of HCC1937 cells treated with Cas9‐Olap RNPs complexed with CMAX for 48 h at 500 nM Cas9. d–f) Combinatorial effect of treating Cas9‐Olap RNPs prepared with the Y373 variant, on anti‐proliferation of cells using conventional carriers for 72 h (500 nM Cas9; n = 3, One‐way ANOVA, ** p < 0.01, *** p < 0.001, **** p < 0.0001). d) Effect of Cas9‐Olap RNPs prepared by conjugation of olaparib via azido (Cas9‐Olap1), sulfhydryl (Cas9‐Olap2), and both azido and sulfhydryl (Cas9‐Olap3) groups, complexed with CMAX and treated to HCC1937 cells. e,f) Comparison of the anti‐proliferation effect in HCC1937 and MDA‐MB‐231 cells using e) CMAX, and f) TAT peptide (molar ratio of Cas9:TAT = 1:10) as the carrier. Concentration of free olaparib was adjusted to the conjugated olaparib concentration for the corresponding Cas9‐Olap conjugate in each group. Cas9‐Olap conjugates were complexed with RAD52 sgRNA at a molar ratio of 1:1.

    Techniques Used: Functional Assay, CRISPR, In Vitro, Mutagenesis, Conjugation Assay, Sequencing, Variant Assay, Comparison, Concentration Assay

    Evaluation of ComBiNE as a self‐delivered nanomedicine platform in cancer cells in vitro. a) Schematic showing the different forms of the ComBiNE platform and delivery to cells. ComBiNE can be prepared from conjugation of Cas9‐AzF with olaparib and CP via the azido and sulfhydryl groups, respectively (Cas9‐Olap1‐CP2), or vice versa (Cas9‐Olap2‐CP1). b,c) Anti‐proliferation effect upon treatment of ComBiNE and control formulations including RAD52 or control sgRNA (NT: non‐target) to HCC1937 cells for 72 h ( n = 3, One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). b) Demonstration of the synergistic effect of ComBiNE compared to Cas9‐CP and Cas9‐Olap conjugate RNPs. c) Comparison of ComBiNE prepared from Cas9‐Olap1‐CP2 and Cas9‐Olap2‐CP1 conjugates. d–f) Functional evaluation of ComBiNE (Cas9‐Olap1‐CP2). d) Western blot analysis showing the expression of RAD52, e) apoptosis levels measured by Annexin V assay, and f) DNA damage measured by the alkaline comet assay, in HCC1937 cells treated with ComBiNE for 48 h (One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). ComBiNE formulations were prepared with the Y373 variant, and RAD52 sgRNA (molar ratio of Cas9:sgRNA = 1:1), followed by treatment at 500 nM Cas9.
    Figure Legend Snippet: Evaluation of ComBiNE as a self‐delivered nanomedicine platform in cancer cells in vitro. a) Schematic showing the different forms of the ComBiNE platform and delivery to cells. ComBiNE can be prepared from conjugation of Cas9‐AzF with olaparib and CP via the azido and sulfhydryl groups, respectively (Cas9‐Olap1‐CP2), or vice versa (Cas9‐Olap2‐CP1). b,c) Anti‐proliferation effect upon treatment of ComBiNE and control formulations including RAD52 or control sgRNA (NT: non‐target) to HCC1937 cells for 72 h ( n = 3, One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). b) Demonstration of the synergistic effect of ComBiNE compared to Cas9‐CP and Cas9‐Olap conjugate RNPs. c) Comparison of ComBiNE prepared from Cas9‐Olap1‐CP2 and Cas9‐Olap2‐CP1 conjugates. d–f) Functional evaluation of ComBiNE (Cas9‐Olap1‐CP2). d) Western blot analysis showing the expression of RAD52, e) apoptosis levels measured by Annexin V assay, and f) DNA damage measured by the alkaline comet assay, in HCC1937 cells treated with ComBiNE for 48 h (One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). ComBiNE formulations were prepared with the Y373 variant, and RAD52 sgRNA (molar ratio of Cas9:sgRNA = 1:1), followed by treatment at 500 nM Cas9.

    Techniques Used: In Vitro, Conjugation Assay, Comparison, Functional Assay, Western Blot, Expressing, Annexin V Assay, Alkaline Single Cell Gel Electrophoresis, Variant Assay

    breast cancer cell lines hcc1937  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC breast cancer cell lines hcc1937
    Breast Cancer Cell Lines Hcc1937, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer cell lines hcc1937/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast cancer cell lines hcc1937 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    cell lines human ductal breast epithelial tumor cells t47d hcc1937  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC cell lines human ductal breast epithelial tumor cells t47d hcc1937
    Cell Lines Human Ductal Breast Epithelial Tumor Cells T47d Hcc1937, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell lines human ductal breast epithelial tumor cells t47d hcc1937/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cell lines human ductal breast epithelial tumor cells t47d hcc1937 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    cancer cell lines human ductal breast epithelial tumor cells t47d hcc1937  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC cancer cell lines human ductal breast epithelial tumor cells t47d hcc1937
    Cancer Cell Lines Human Ductal Breast Epithelial Tumor Cells T47d Hcc1937, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cancer cell lines human ductal breast epithelial tumor cells t47d hcc1937/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cancer cell lines human ductal breast epithelial tumor cells t47d hcc1937 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    cell lines human ductal breast epithelial tumor cells t47d hcc1937  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC cell lines human ductal breast epithelial tumor cells t47d hcc1937
    Cell Lines Human Ductal Breast Epithelial Tumor Cells T47d Hcc1937, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell lines human ductal breast epithelial tumor cells t47d hcc1937/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cell lines human ductal breast epithelial tumor cells t47d hcc1937 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    ATCC hcc1937 crl 2336 human breast cancer cells
    SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and <t>HCC1937</t> breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.
    Hcc1937 Crl 2336 Human Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1937 crl 2336 human breast cancer cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1937 crl 2336 human breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Thermo Fisher breast cancer cell line hcc1937
    SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and <t>HCC1937</t> breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.
    Breast Cancer Cell Line Hcc1937, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer cell line hcc1937/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast cancer cell line hcc1937 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Korean Cell Line Bank hcc1937 human breast cancer cells
    SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and <t>HCC1937</t> breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.
    Hcc1937 Human Breast Cancer Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1937 human breast cancer cells/product/Korean Cell Line Bank
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1937 human breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    ATCC hcc1937 breast cancer cells
    CAFs conferred more potential to breast cancer cells in growth and chemoresistance than NFs. (a) Impact of coculture with NFs or CAFs on the growth of <t>HCC1937</t> breast cancer cells. (b) Influence of coculture with NFs or CAFs on the sensitivity of HCC1937 breast cancer cells to doxorubicin. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Hcc1937 Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcc1937 breast cancer cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hcc1937 breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Korean Cell Line Bank brca1 deficient hcc1937 human breast cancer cells
    Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of <t>BRCA1‐mutant</t> <t>HCC1937</t> breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.
    Brca1 Deficient Hcc1937 Human Breast Cancer Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/brca1 deficient hcc1937 human breast cancer cells/product/Korean Cell Line Bank
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    brca1 deficient hcc1937 human breast cancer cells - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    ATCC breast cancer cell lines hcc1937
    Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of <t>BRCA1‐mutant</t> <t>HCC1937</t> breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.
    Breast Cancer Cell Lines Hcc1937, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer cell lines hcc1937/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    breast cancer cell lines hcc1937 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    ATCC cell lines human ductal breast epithelial tumor cells t47d hcc1937
    Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of <t>BRCA1‐mutant</t> <t>HCC1937</t> breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.
    Cell Lines Human Ductal Breast Epithelial Tumor Cells T47d Hcc1937, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell lines human ductal breast epithelial tumor cells t47d hcc1937/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cell lines human ductal breast epithelial tumor cells t47d hcc1937 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    ATCC cancer cell lines human ductal breast epithelial tumor cells t47d hcc1937
    Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of <t>BRCA1‐mutant</t> <t>HCC1937</t> breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.
    Cancer Cell Lines Human Ductal Breast Epithelial Tumor Cells T47d Hcc1937, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cancer cell lines human ductal breast epithelial tumor cells t47d hcc1937/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cancer cell lines human ductal breast epithelial tumor cells t47d hcc1937 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.

    Journal: Scientific Reports

    Article Title: Impact of in vitro SARS-CoV-2 infection on breast cancer cells

    doi: 10.1038/s41598-024-63804-3

    Figure Lengend Snippet: SARS-CoV-2 replication in breast cancer cell lines. Western blot and densitometric analysis of ( a ) ACE2 and ( b ) NRP1 protein expression in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines. ( c ) ACE2 and NRP1 were silenced by siRNAs in the MCF7, MDA-MB-231 and HCC1937 breast cancer cell lines, which were subsequently infected with SARS-CoV-2 lineage B1. Viral RNA, expressed as copies/100 ng RNA, was quantified in the cytoplasm 6 h p.i. by real-time PCR with primers targeting the viral N1 gene. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance. ( d ) MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2, and viral RNA was quantified at different time points in the cytoplasm and in the supernatants by real-time PCR. The viral load is expressed as copies/100 ng RNA or copies/mL for the cellular or supernatant RNA, respectively. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 according to two-way ANOVA with multiple comparisons; refers to the comparison between MCF7 cells and MDA-MB-231 cells and the comparison between MCF7 cells and HCC1937 cells.

    Article Snippet: MCF7 (HTB-22), MDA-MB-231 (CRM-HTB-26), and HCC1937 (CRL-2336) human breast cancer cells and VERO E6 normal monkey kidney cells (CRL-1586) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Western Blot, Expressing, Infection, Real-time Polymerase Chain Reaction, Comparison

    Effect of SARS-CoV-2 infection on breast cancer cell proliferation and motility. ( a ) MTT proliferation assay of MCF7, MDA-MB-231 and HCC1937 breast cancer cells after 72 h or 7 days of SARS-CoV-2 infection. Uninfected cells served as controls. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 by unpaired two-tailed t test. ( b ) Confluent monolayers of MCF7, MDA-MB-231 and HCC1937 cells were infected with SARS-CoV-2. After 2 h of infection, the viral inoculum was removed, and gap wounds were generated by mechanical scratching. Cell migration into the wounded area was observed at 0, 4 and 24 h p.i. Histograms showing the extent of wound closure at the indicated time points are presented, with data shown as the percentages of wound closure at a specific time point compared to 0 h. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance.

    Journal: Scientific Reports

    Article Title: Impact of in vitro SARS-CoV-2 infection on breast cancer cells

    doi: 10.1038/s41598-024-63804-3

    Figure Lengend Snippet: Effect of SARS-CoV-2 infection on breast cancer cell proliferation and motility. ( a ) MTT proliferation assay of MCF7, MDA-MB-231 and HCC1937 breast cancer cells after 72 h or 7 days of SARS-CoV-2 infection. Uninfected cells served as controls. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. *** p < 0.001 by unpaired two-tailed t test. ( b ) Confluent monolayers of MCF7, MDA-MB-231 and HCC1937 cells were infected with SARS-CoV-2. After 2 h of infection, the viral inoculum was removed, and gap wounds were generated by mechanical scratching. Cell migration into the wounded area was observed at 0, 4 and 24 h p.i. Histograms showing the extent of wound closure at the indicated time points are presented, with data shown as the percentages of wound closure at a specific time point compared to 0 h. The data are presented as the means ± SEMs and are representative of one of three independent experiments with similar results. * p < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test with a single pooled variance.

    Article Snippet: MCF7 (HTB-22), MDA-MB-231 (CRM-HTB-26), and HCC1937 (CRL-2336) human breast cancer cells and VERO E6 normal monkey kidney cells (CRL-1586) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Infection, Proliferation Assay, Two Tailed Test, Generated, Migration, Comparison

    Effect of SARS-CoV-2 infection on breast cancer cell gene expression profiles. MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2 lineage B1, and gene expression profile analysis was performed at 24 h and 7 days p.i. ( a ) Number of DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cell line 24 h p.i. ( b ) Overlapping upregulated DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cellular model 24 h p.i. ( c-e ) Bubble plots of the top 10 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected cells as determined by preranked GSEA. ( f ) Bubble plot of the only 4 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected HCC1937 cells at 7 days p.i., as determined by preranked GSEA. The X-axis shows the normalized enrichment score (NES). The bubble area is proportional to the size of the gene set, and the bubble color represents the FDR q value.

    Journal: Scientific Reports

    Article Title: Impact of in vitro SARS-CoV-2 infection on breast cancer cells

    doi: 10.1038/s41598-024-63804-3

    Figure Lengend Snippet: Effect of SARS-CoV-2 infection on breast cancer cell gene expression profiles. MCF7, MDA-MB-231 and HCC1937 breast cancer cells were infected with SARS-CoV-2 lineage B1, and gene expression profile analysis was performed at 24 h and 7 days p.i. ( a ) Number of DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cell line 24 h p.i. ( b ) Overlapping upregulated DEGs (FDR < 0.05) identified by the comparison of infected and control cells of each cellular model 24 h p.i. ( c-e ) Bubble plots of the top 10 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected cells as determined by preranked GSEA. ( f ) Bubble plot of the only 4 Reactome pathways with an FDR q-value < 0.05 found to be enriched in infected cells versus uninfected HCC1937 cells at 7 days p.i., as determined by preranked GSEA. The X-axis shows the normalized enrichment score (NES). The bubble area is proportional to the size of the gene set, and the bubble color represents the FDR q value.

    Article Snippet: MCF7 (HTB-22), MDA-MB-231 (CRM-HTB-26), and HCC1937 (CRL-2336) human breast cancer cells and VERO E6 normal monkey kidney cells (CRL-1586) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Infection, Expressing, Comparison

    CAFs conferred more potential to breast cancer cells in growth and chemoresistance than NFs. (a) Impact of coculture with NFs or CAFs on the growth of HCC1937 breast cancer cells. (b) Influence of coculture with NFs or CAFs on the sensitivity of HCC1937 breast cancer cells to doxorubicin. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Heliyon

    Article Title: Biological differences between normal and cancer-associated fibroblasts in breast cancer

    doi: 10.1016/j.heliyon.2023.e19803

    Figure Lengend Snippet: CAFs conferred more potential to breast cancer cells in growth and chemoresistance than NFs. (a) Impact of coculture with NFs or CAFs on the growth of HCC1937 breast cancer cells. (b) Influence of coculture with NFs or CAFs on the sensitivity of HCC1937 breast cancer cells to doxorubicin. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Briefly, HCC1937 breast cancer cells (ATCC, USA) were cultivated in RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin and maintained at 37 °C in a humidified environment with 5% CO 2 .

    Techniques:

    CAFs conferred more potential to breast cancer cells in migration and invasion than NFs. Representative photomicrographs (a, b) and quantification (c–e) depicting the migration (a) and invasion (b) under distinct coculture conditions for HCC1937 cells as assessed through transwell assay. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Heliyon

    Article Title: Biological differences between normal and cancer-associated fibroblasts in breast cancer

    doi: 10.1016/j.heliyon.2023.e19803

    Figure Lengend Snippet: CAFs conferred more potential to breast cancer cells in migration and invasion than NFs. Representative photomicrographs (a, b) and quantification (c–e) depicting the migration (a) and invasion (b) under distinct coculture conditions for HCC1937 cells as assessed through transwell assay. Each experiment was replicated three times, and data are presented as mean ± SD. Statistical analysis was performed using a one-way ANOVA test, where p < 0.05 indicated statistical significance. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Briefly, HCC1937 breast cancer cells (ATCC, USA) were cultivated in RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin and maintained at 37 °C in a humidified environment with 5% CO 2 .

    Techniques: Migration, Transwell Assay

    Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of BRCA1‐mutant HCC1937 breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.

    Journal: Advanced Science

    Article Title: Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform

    doi: 10.1002/advs.202302253

    Figure Lengend Snippet: Delivery of ComBiNE for gene editing in vitro. ComBiNE and control formulations were formed using conjugates of the Y373 variant, and complexation with sgRNA targeting RAD52 (molar ratio of Cas9:sgRNA = 1:1). a) Confocal microscopy of BRCA1‐mutant HCC1937 breast cancer cells treated with ComBiNE or control formulations for 4 h at 500 nM Cas9 (blue: DAPI, green: F‐actin, red: Cas9 labeled with AF647; scale bar: 50 µm). b) Quantification of uptake efficiencies by image analysis of (a). c) sgRNA design for the RAD52 gene (blue: sgRNA sequence, black: target sequence of RAD52 gene, green: PAM sequence, red arrowhead: cleavage site). d) Cleavage activities examined by treating Cas9 conjugate RNPs to RAD52 target DNA, and analysis of cleaved DNA fragments. e) Gene editing efficiencies, and f) representative sequence data (green: PAM, ‐: deletion, red: insertion, WT: wild‐type) of HCC1937 cells treated with ComBiNE and control formulations for 48 h at 500 nM Cas9, and targeted deep sequencing analysis. For (e), indel types with frequency values of > 0.5% for at least one formulation are shown in different colors in the stacked bars.

    Article Snippet: BRCA1‐deficient HCC1937 human breast cancer cells with the 5382C mutation and MDA‐MB‐231 human epithelial breast cancer cells were obtained from the Korean Cell Line Bank.

    Techniques: In Vitro, Variant Assay, Confocal Microscopy, Mutagenesis, Labeling, Sequencing, Formulation

    Functional validation of CRISPR/Cas9‐drug conjugates for combination treatment in cancer cells in vitro. a) Schematic showing the principle of synthetic lethality induced by Cas9‐Olap conjugate RNPs, based on the function of olaparib and RAD52 gene editing in BRCA‐mutant cancer. b) Characterization of Cas9‐Olap conjugates prepared with the various Cas9‐AzF variants: olaparib conjugation efficiencies, cleavage activities, and indel frequencies. c) Representative sequence data by targeting deep sequencing of HCC1937 cells treated with Cas9‐Olap RNPs complexed with CMAX for 48 h at 500 nM Cas9. d–f) Combinatorial effect of treating Cas9‐Olap RNPs prepared with the Y373 variant, on anti‐proliferation of cells using conventional carriers for 72 h (500 nM Cas9; n = 3, One‐way ANOVA, ** p < 0.01, *** p < 0.001, **** p < 0.0001). d) Effect of Cas9‐Olap RNPs prepared by conjugation of olaparib via azido (Cas9‐Olap1), sulfhydryl (Cas9‐Olap2), and both azido and sulfhydryl (Cas9‐Olap3) groups, complexed with CMAX and treated to HCC1937 cells. e,f) Comparison of the anti‐proliferation effect in HCC1937 and MDA‐MB‐231 cells using e) CMAX, and f) TAT peptide (molar ratio of Cas9:TAT = 1:10) as the carrier. Concentration of free olaparib was adjusted to the conjugated olaparib concentration for the corresponding Cas9‐Olap conjugate in each group. Cas9‐Olap conjugates were complexed with RAD52 sgRNA at a molar ratio of 1:1.

    Journal: Advanced Science

    Article Title: Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform

    doi: 10.1002/advs.202302253

    Figure Lengend Snippet: Functional validation of CRISPR/Cas9‐drug conjugates for combination treatment in cancer cells in vitro. a) Schematic showing the principle of synthetic lethality induced by Cas9‐Olap conjugate RNPs, based on the function of olaparib and RAD52 gene editing in BRCA‐mutant cancer. b) Characterization of Cas9‐Olap conjugates prepared with the various Cas9‐AzF variants: olaparib conjugation efficiencies, cleavage activities, and indel frequencies. c) Representative sequence data by targeting deep sequencing of HCC1937 cells treated with Cas9‐Olap RNPs complexed with CMAX for 48 h at 500 nM Cas9. d–f) Combinatorial effect of treating Cas9‐Olap RNPs prepared with the Y373 variant, on anti‐proliferation of cells using conventional carriers for 72 h (500 nM Cas9; n = 3, One‐way ANOVA, ** p < 0.01, *** p < 0.001, **** p < 0.0001). d) Effect of Cas9‐Olap RNPs prepared by conjugation of olaparib via azido (Cas9‐Olap1), sulfhydryl (Cas9‐Olap2), and both azido and sulfhydryl (Cas9‐Olap3) groups, complexed with CMAX and treated to HCC1937 cells. e,f) Comparison of the anti‐proliferation effect in HCC1937 and MDA‐MB‐231 cells using e) CMAX, and f) TAT peptide (molar ratio of Cas9:TAT = 1:10) as the carrier. Concentration of free olaparib was adjusted to the conjugated olaparib concentration for the corresponding Cas9‐Olap conjugate in each group. Cas9‐Olap conjugates were complexed with RAD52 sgRNA at a molar ratio of 1:1.

    Article Snippet: BRCA1‐deficient HCC1937 human breast cancer cells with the 5382C mutation and MDA‐MB‐231 human epithelial breast cancer cells were obtained from the Korean Cell Line Bank.

    Techniques: Functional Assay, CRISPR, In Vitro, Mutagenesis, Conjugation Assay, Sequencing, Variant Assay, Comparison, Concentration Assay

    Evaluation of ComBiNE as a self‐delivered nanomedicine platform in cancer cells in vitro. a) Schematic showing the different forms of the ComBiNE platform and delivery to cells. ComBiNE can be prepared from conjugation of Cas9‐AzF with olaparib and CP via the azido and sulfhydryl groups, respectively (Cas9‐Olap1‐CP2), or vice versa (Cas9‐Olap2‐CP1). b,c) Anti‐proliferation effect upon treatment of ComBiNE and control formulations including RAD52 or control sgRNA (NT: non‐target) to HCC1937 cells for 72 h ( n = 3, One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). b) Demonstration of the synergistic effect of ComBiNE compared to Cas9‐CP and Cas9‐Olap conjugate RNPs. c) Comparison of ComBiNE prepared from Cas9‐Olap1‐CP2 and Cas9‐Olap2‐CP1 conjugates. d–f) Functional evaluation of ComBiNE (Cas9‐Olap1‐CP2). d) Western blot analysis showing the expression of RAD52, e) apoptosis levels measured by Annexin V assay, and f) DNA damage measured by the alkaline comet assay, in HCC1937 cells treated with ComBiNE for 48 h (One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). ComBiNE formulations were prepared with the Y373 variant, and RAD52 sgRNA (molar ratio of Cas9:sgRNA = 1:1), followed by treatment at 500 nM Cas9.

    Journal: Advanced Science

    Article Title: Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform

    doi: 10.1002/advs.202302253

    Figure Lengend Snippet: Evaluation of ComBiNE as a self‐delivered nanomedicine platform in cancer cells in vitro. a) Schematic showing the different forms of the ComBiNE platform and delivery to cells. ComBiNE can be prepared from conjugation of Cas9‐AzF with olaparib and CP via the azido and sulfhydryl groups, respectively (Cas9‐Olap1‐CP2), or vice versa (Cas9‐Olap2‐CP1). b,c) Anti‐proliferation effect upon treatment of ComBiNE and control formulations including RAD52 or control sgRNA (NT: non‐target) to HCC1937 cells for 72 h ( n = 3, One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). b) Demonstration of the synergistic effect of ComBiNE compared to Cas9‐CP and Cas9‐Olap conjugate RNPs. c) Comparison of ComBiNE prepared from Cas9‐Olap1‐CP2 and Cas9‐Olap2‐CP1 conjugates. d–f) Functional evaluation of ComBiNE (Cas9‐Olap1‐CP2). d) Western blot analysis showing the expression of RAD52, e) apoptosis levels measured by Annexin V assay, and f) DNA damage measured by the alkaline comet assay, in HCC1937 cells treated with ComBiNE for 48 h (One‐way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001). ComBiNE formulations were prepared with the Y373 variant, and RAD52 sgRNA (molar ratio of Cas9:sgRNA = 1:1), followed by treatment at 500 nM Cas9.

    Article Snippet: BRCA1‐deficient HCC1937 human breast cancer cells with the 5382C mutation and MDA‐MB‐231 human epithelial breast cancer cells were obtained from the Korean Cell Line Bank.

    Techniques: In Vitro, Conjugation Assay, Comparison, Functional Assay, Western Blot, Expressing, Annexin V Assay, Alkaline Single Cell Gel Electrophoresis, Variant Assay